Biotech Firms In China, India, Brazil Thriving; Time For Big Pharma To Step In?
This article was originally published in PharmAsia News
By addressing local health challenges and leveraging cost-efficiency in research and development, biotech firms in emerging China, India, Brazil and South Africa (BRISA) are growing faster than ever. Global drug makers can benefit in these markets by sharing expertise and forming collaborations with these companies, say health researchers Rahim Razaie and Peter Singer at the Mclaughlin-Rotman Center for Global Health at the University of Toronto
You may also be interested in...
With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).